Evidence map›Paper›PMID 40620732›Full record

ArticleThe breast journal2025

Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups.

Erkan Ozcan, Ivo Gokmen, Fahri Akgul, Fatma Akdag Kahvecioglu, Abdussamet Celebi, Osman Kostek, Ilhan Hacıbekiroglu, Bulent Erdogan

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The breast journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Investigation of the prevalence of HER2-ultralow and the effects of HER2 status (HER2-null vs. HER2-ultralow) on survival in HER2-negative early-stage breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Erkan OzcanDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.ORCID 0000-0003-1562-6340
Ivo GokmenDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.ORCID 0000-0002-0382-5396
Fahri AkgulDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Fatma Akdag KahveciogluDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
Abdussamet CelebiDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Osman KostekDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Ilhan HacıbekirogluDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
Bulent ErdoganDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.ORCID 0000-0002-2158-3490

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMiddle AgedNeoplasm MetastasisProgression-Free SurvivalReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneCDK4/6 inhibitorsHER2 lowHER2 zeroHR-positive breast cancerprogression-free survival

Identifiers

PMID40620732
PMCPMC12227261

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.